Order Now: brent@sdlifesciences.com
Anti-Cytokeratin 14/17 antibody |
STJ98650 |
St John's Laboratory |
200 µl |
EUR 236.4 |
Description: Rabbit polyclonal to Cytokeratin 14/17. |
Cytokeratin 14 (Cytokeratin 14) Antibody |
20-abx009056 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
20-abx121588 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
abx232195-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
abx232196-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
abx232197-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
Cytokeratin 17 Polyclonal Antibody |
40822-100ul |
SAB |
100ul |
EUR 302.4 |
Cytokeratin 17 Polyclonal Antibody |
40822-50ul |
SAB |
50ul |
EUR 224.4 |
Cytokeratin 17 Polyclonal Antibody |
ABP51128-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of Cytokeratin 17 from Human, Mouse, Rat. This Cytokeratin 17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 17 at AA range: 350-430 |
Cytokeratin 17 Polyclonal Antibody |
ABP51128-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 17 from Human, Mouse, Rat. This Cytokeratin 17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 17 at AA range: 350-430 |
Cytokeratin 17 Polyclonal Antibody |
ABP51128-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 17 from Human, Mouse, Rat. This Cytokeratin 17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 17 at AA range: 350-430 |
Cytokeratin 17 Polyclonal Antibody |
ES2127-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 17 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Cytokeratin 17 Polyclonal Antibody |
ES2127-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 17 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Cytokeratin 14 Polyclonal Antibody |
41582-100ul |
SAB |
100ul |
EUR 302.4 |
Cytokeratin 14 Polyclonal Antibody |
41582-50ul |
SAB |
50ul |
EUR 224.4 |
Cytokeratin 14 Polyclonal Antibody |
ABP55033-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Cytokeratin 14 |
Cytokeratin 14 Polyclonal Antibody |
ABP55033-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Cytokeratin 14 |
Cytokeratin 14 Polyclonal Antibody |
ABP55033-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Cytokeratin 14 |
Cytokeratin 14 Polyclonal Antibody |
ABP52904-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 14 |
Cytokeratin 14 Polyclonal Antibody |
ABP52904-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 14 |
Cytokeratin 14 Polyclonal Antibody |
ABP52904-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14 from Human, Mouse, Rat. This Cytokeratin 14 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Cytokeratin 14 |
Cytokeratin 14 Polyclonal Antibody |
ES3903-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
Cytokeratin 14 Polyclonal Antibody |
ES3903-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
Cytokeratin 14 Polyclonal Antibody |
ES6032-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
Cytokeratin 14 Polyclonal Antibody |
ES6032-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 14 from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA |
Cytokeratin 17 Rabbit mAb |
A3769 |
Abclonal |
20 μL |
EUR 18 |
Cytokeratin 17 Rabbit mAb |
A3769-100ul |
Abclonal |
100 ul |
EUR 492 |
Cytokeratin 17 Rabbit mAb |
A3769-200ul |
Abclonal |
200 ul |
EUR 685.2 |
Cytokeratin 17 Rabbit mAb |
A3769-20ul |
Abclonal |
20 ul |
EUR 265.2 |
Cytokeratin 17 Rabbit mAb |
A3769-50ul |
Abclonal |
50 ul |
EUR 344.4 |
Cytokeratin 14 Rabbit mAb |
A19039-100ul |
Abclonal |
100 ul |
EUR 492 |
Cytokeratin 14 Rabbit mAb |
A19039-200ul |
Abclonal |
200 ul |
EUR 685.2 |
Cytokeratin 14 Rabbit mAb |
A19039-20ul |
Abclonal |
20 ul |
EUR 265.2 |
Cytokeratin 14 Rabbit mAb |
A19039-50ul |
Abclonal |
50 ul |
EUR 344.4 |
Cytokeratin 17 Polyclonal Conjugated Antibody |
C40822 |
SAB |
100ul |
EUR 476.4 |
Cytokeratin 14/16 Polyclonal Antibody |
ABP55034-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14/16 from Human, Mouse, Rat. This Cytokeratin 14/16 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Cytokeratin 14/16 at AA rangle: 1-80 |
Cytokeratin 14/16 Polyclonal Antibody |
ABP55034-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14/16 from Human, Mouse, Rat. This Cytokeratin 14/16 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Cytokeratin 14/16 at AA rangle: 1-80 |
Cytokeratin 14/16 Polyclonal Antibody |
ABP55034-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin 14/16 from Human, Mouse, Rat. This Cytokeratin 14/16 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human Cytokeratin 14/16 at AA rangle: 1-80 |
Cytokeratin 14 (KRT14) polyclonal antibody |
ABP-PAB-11625 |
Allele Biotech |
100 ug |
Ask for price |
|
Cytokeratin 14 Polyclonal Conjugated Antibody |
C41582 |
SAB |
100ul |
EUR 476.4 |
Cytokeratin 14/16 Polyclonal Antibody |
ES6033-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 14/16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Cytokeratin 14/16 Polyclonal Antibody |
ES6033-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against Cytokeratin 14/16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Anti-Cytokeratin 17 Rabbit Monoclonal Antibody |
M02289-1 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Rabbit Monoclonal Cytokeratin 17 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat. |
Anti-Cytokeratin 14 Rabbit Monoclonal Antibody |
M01432-1 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Rabbit Monoclonal Cytokeratin 14 Antibody. Validated in IP, IF, WB and tested in Human. |
Anti-Cytokeratin 14 Rabbit Monoclonal Antibody |
M01432-2 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Rabbit Monoclonal Cytokeratin 14 Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat. |
Cytokeratin 17 antibody |
70R-49983 |
Fitzgerald |
100 ul |
EUR 292.8 |
Description: Purified Polyclonal Cytokeratin 17 antibody |
Cytokeratin 17 antibody |
70R-3229 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Rabbit polyclonal Cytokeratin 17 antibody raised against the C terminal of KRT17 |
Cytokeratin 17 Antibody |
48633-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 17 Antibody |
48633-50ul |
SAB |
50ul |
EUR 286.8 |
Cytokeratin 17 antibody |
10R-7971 |
Fitzgerald |
100 ug |
EUR 457.2 |
Description: Mouse monoclonal Cytokeratin 17 antibody |
Cytokeratin 17 antibody |
10R-C160a |
Fitzgerald |
50 ug |
EUR 534 |
Description: Mouse monoclonal Cytokeratin 17 antibody |
Cytokeratin 17 Antibody |
AF7851 |
Affbiotech |
200ul |
EUR 540 |
Cytokeratin 17 Antibody |
DF6898 |
Affbiotech |
200ul |
EUR 420 |
Cytokeratin 17 Antibody |
AF5480 |
Affbiotech |
200ul |
EUR 420 |
Cytokeratin 17 Antibody |
AF0190 |
Affbiotech |
200ul |
EUR 420 |
Cytokeratin 17 Antibody |
V2176-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V2176-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V2176IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V2176SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V2669-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V2669-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V2669IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V2669SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V7128-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki] |
Cytokeratin 17 Antibody |
V7128-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki] |
Cytokeratin 17 Antibody |
V7128IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki] |
Cytokeratin 17 Antibody |
V7128SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 is a type I keratin. It is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. [Wiki] |
Cytokeratin 17 Antibody |
V8796-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells ofcomplex epithelia but not in stratified orsimple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V8796-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells ofcomplex epithelia but not in stratified orsimple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V8796SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells ofcomplex epithelia but not in stratified orsimple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V9059-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V9059-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V9059IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V9059SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V9167-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V9167-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 17 Antibody |
V9167SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype. |
Cytokeratin 14 antibody |
70R-49981 |
Fitzgerald |
100 ul |
EUR 292.8 |
Description: Purified Polyclonal Cytokeratin 14 antibody |
Cytokeratin 14 Antibody |
48956-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 14 Antibody |
48956-50ul |
SAB |
50ul |
EUR 286.8 |
Cytokeratin 14 antibody |
20R-CP002 |
Fitzgerald |
100 ul |
EUR 676.8 |
Description: Guinea Pig polyclonal Cytokeratin 14 antibody |
Cytokeratin 14 antibody |
10R-7970 |
Fitzgerald |
100 ug |
EUR 444 |
Description: Mouse monoclonal Cytokeratin 14 antibody |
Cytokeratin 14 antibody |
10R-C159a |
Fitzgerald |
100 ug |
EUR 766.8 |
Description: Mouse monoclonal Cytokeratin 14 antibody |
Cytokeratin 14 Antibody |
AF5225 |
Affbiotech |
200ul |
EUR 420 |
Cytokeratin 14 Antibody |
AF5370 |
Affbiotech |
200ul |
EUR 420 |
Cytokeratin 14 (KRT14) Rabbit mAb |
A19039 |
Abclonal |
20 μL |
EUR 18 |
Anti-Cytokeratin 17 (CK-17) Rabbit Monoclonal Antibody (RM351) |
A1849-50 |
Biovision |
|
EUR 385.2 |
Anti-CK-14 (Cytokeratin-14) Rabbit Monoclonal Antibody (RM328) |
A1842-50 |
Biovision |
|
EUR 373.2 |
Polyclonal KRT14 / CK14 / Cytokeratin 14 Antibody |
APR03031G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human KRT14 / CK14 / Cytokeratin 14 . This antibody is tested and proven to work in the following applications: |
Human Cytokeratin-17 (CK-17) Antibody |
32066-05111 |
AssayPro |
150 ug |
EUR 313.2 |
Anti-Cytokeratin 17 (CK-17) Rabbit Monoclonal Antibody, Clone#RM351 |
M02101-3 |
BosterBio |
100uL |
EUR 476.4 |
Description: Anti-Cytokeratin 17 (CK-17) Rabbit Monoclonal Antibody, Clone#RM351 tested in WB, IHC, reactive to Human |
Anti-CK-14 (Cytokeratin-14) Rabbit Monoclonal Antibody, Clone#RM328 |
M01432-3 |
BosterBio |
100uL |
EUR 462 |
Description: Anti-CK-14 (Cytokeratin-14) Rabbit Monoclonal Antibody, Clone#RM328 tested in WB, IHC, reactive to Human
(Mouse or Rat) |
Cytokeratin 7+17 Antibody |
abx139682-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
Cytokeratin 17 (CK17) Antibody |
20-abx134382 |
Abbexa |
-
EUR 427.20
-
EUR 644.40
-
EUR 260.40
|
|
|
Cytokeratin 17 (CK17) Antibody |
20-abx009054 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Cytokeratin-17 (CK17) Antibody |
abx019067-100ug |
Abbexa |
100 ug |
EUR 410.4 |
|
Cytokeratin-17 (CK17) Antibody |
abx413464-02ml |
Abbexa |
0.2 ml |
EUR 460.8 |
|
Cytokeratin 17 (CK17) Antibody |
abx232201-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Cytokeratin 17 (CK17) Antibody |
abx232202-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
Cytokeratin 17-Specific Antibody |
abx232203-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Cytokeratin 17(E3) Antibody |
BNC040158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF405S conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC040158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF405S conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC050158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF405M conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC050158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF405M conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCAP0158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCAP0158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCB0158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), Biotin conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCB0158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), Biotin conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCP0158-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Cytokeratin 17(E3), PerCP conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCR0158-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Cytokeratin 17(E3), RPE conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC940158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF594 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC940158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF594 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCA0158-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Cytokeratin 17(E3), APC conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC810158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF680R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC810158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF680R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNUB0158-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against Cytokeratin 17(E3), Concentration: 0.2mg/mL |
Cytokeratin 17(E3) Antibody |
BNUB0158-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against Cytokeratin 17(E3), Concentration: 0.2mg/mL |
Cytokeratin 17(E3) Antibody |
BNCH0158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNCH0158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC880158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF488A conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC880158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF488A conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17 Conjugated Antibody |
C48633 |
SAB |
100ul |
EUR 476.4 |
Cytokeratin 17(E3) Antibody |
BNC680158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF568 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC680158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF568 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC470158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF647 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC470158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF647 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC430158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF543 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC430158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF543 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC610158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF660R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC610158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF660R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC800158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF680 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC800158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF680 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC400158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF640R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC400158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF640R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC550158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF555 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC550158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF555 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC700158-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF770 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNC700158-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 17(E3), CF770 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 17(E3) Antibody |
BNUM0158-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against Cytokeratin 17(E3), 1mg/mL |
anti- Cytokeratin 17 antibody |
FNab02201 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against Cytokeratin 17 |
anti- Cytokeratin 17 antibody |
FNab02202 |
FN Test |
100µg |
EUR 702 |
|
Description: Antibody raised against Cytokeratin 17 |
Anti-Cytokeratin 17 antibody |
STJ92630 |
St John's Laboratory |
200 µl |
EUR 236.4 |
Description: Rabbit polyclonal to Cytokeratin 17. |
Anti-Cytokeratin 17 antibody |
STJ97983 |
St John's Laboratory |
100 µl |
EUR 280.8 |
Description: Mouse monoclonal to Cytokeratin 17. |
Cytokeratin 7/17 Antibody |
V8298-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: It recognizes intermediate filament proteins (IFP's) of 55kDa and 46kDa, which are identified as Cytokeratin 7 and Cytokeratin 17 respectively. On formalin-fixed, paraffin embedded sections, C-46 reacts with Keratin 7 only. Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 7 is a basic cytokeratin, which is found in most glandular and transitional epithelia but not in the stratified squamous epithelia. Cytokeratin 7 is expressed in the epithelial cells of ovary, lung, and breast but not of colon, prostate, or gastrointestinal tract. Cytokeratin 17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. Cytokeratin 17 antibody marks basal cell differentiation. |
Cytokeratin 7/17 Antibody |
V8298-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: It recognizes intermediate filament proteins (IFP's) of 55kDa and 46kDa, which are identified as Cytokeratin 7 and Cytokeratin 17 respectively. On formalin-fixed, paraffin embedded sections, C-46 reacts with Keratin 7 only. Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 7 is a basic cytokeratin, which is found in most glandular and transitional epithelia but not in the stratified squamous epithelia. Cytokeratin 7 is expressed in the epithelial cells of ovary, lung, and breast but not of colon, prostate, or gastrointestinal tract. Cytokeratin 17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. Cytokeratin 17 antibody marks basal cell differentiation. |
Cytokeratin 7/17 Antibody |
V8298SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: It recognizes intermediate filament proteins (IFP's) of 55kDa and 46kDa, which are identified as Cytokeratin 7 and Cytokeratin 17 respectively. On formalin-fixed, paraffin embedded sections, C-46 reacts with Keratin 7 only. Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 7 is a basic cytokeratin, which is found in most glandular and transitional epithelia but not in the stratified squamous epithelia. Cytokeratin 7 is expressed in the epithelial cells of ovary, lung, and breast but not of colon, prostate, or gastrointestinal tract. Cytokeratin 17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. Cytokeratin 17 antibody marks basal cell differentiation. |
Cytokeratin 14(LL002) Antibody |
BNC040499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF405S conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC040499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF405S conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC050499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF405M conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC050499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF405M conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCAP0499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCAP0499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCB0499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), Biotin conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCB0499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), Biotin conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCP0499-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Cytokeratin 14(LL002), PerCP conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCR0499-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Cytokeratin 14(LL002), RPE conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC940499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF594 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC940499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF594 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCA0499-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Cytokeratin 14(LL002), APC conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC810499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF680R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC810499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF680R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNUB0499-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against Cytokeratin 14(LL002), Concentration: 0.2mg/mL |
Cytokeratin 14(LL002) Antibody |
BNUB0499-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against Cytokeratin 14(LL002), Concentration: 0.2mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCH0499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNCH0499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC880499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF488A conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC880499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF488A conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14 Conjugated Antibody |
C48956 |
SAB |
100ul |
EUR 476.4 |
Cytokeratin 14(LL002) Antibody |
BNC680499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF568 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC680499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF568 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC470499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF647 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC470499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF647 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC400499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF640R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC400499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF640R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC430499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF543 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC430499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF543 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC610499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF660R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC610499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF660R conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC800499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF680 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC800499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF680 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC550499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF555 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC550499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF555 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC700499-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF770 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNC700499-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Cytokeratin 14(LL002), CF770 conjugate, Concentration: 0.1mg/mL |
Cytokeratin 14(LL002) Antibody |
BNUM0499-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against Cytokeratin 14(LL002), 1mg/mL |